2024
Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas
Tabor J, O'Brien J, Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas. Neurosurgery 2024, 70: 203-203. DOI: 10.1227/neu.0000000000002810_112.Peer-Reviewed Original ResearchProgression-free survivalHigh-grade meningiomasOverall survivalNF2 mutationsDecreased PFSLow grade meningiomasWHO grading criteriaLow-grade meningiomasAssociated with recurrenceSomatic NF2 mutationsHigher recurrence rateSomatic driver mutationsAggressive clinical characteristicsIncreased chromosomal instabilityLoss of CDKN2A/BHigh-copy number variationCDKN2A mutationsCopy number variationsAggressive meningiomasLow-grade onesProliferative indexCDKN2A lossGrade meningiomasRecurrence rateMitotic count
2023
EPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS
Tabor J, Chavez M, O'Brien J, Morales-Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. EPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS. Neuro-Oncology 2023, 25: v134-v135. PMCID: PMC10639255, DOI: 10.1093/neuonc/noad179.0509.Peer-Reviewed Original ResearchProgression-free survivalShorter progression-free survivalHigh recurrence rateHigh-grade meningiomasCDKN2A/BOverall survivalRecurrence rateLow-grade meningiomasHeterozygous lossNF2 mutationsHigh mitotic countFree survivalMethods ClinicalSomatic NF2 mutationsClinical associationsLower OSHigh recurrenceLow-grade onesProliferative indexMitotic countAggressive meningiomasClinical implicationsMeningiomasPotential associationSkull base
2021
Temporal and spatial topography of cell proliferation in cancer.
Kabraji S, Gaglia G, Argyropoulou D, Dai Y, Wang S, Bergholz J, Coy S, Lin J, Jeselsohn R, Metzger O, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Journal Of Clinical Oncology 2021, 39: 3122-3122. DOI: 10.1200/jco.2021.39.15_suppl.3122.Peer-Reviewed Original ResearchCell cycle stateCancer cellsBreast cancerTumor-infiltrating immune cellsDisease-free survivalCell cycle protein expressionCell proliferationDormant cancer cellsCancer cell proliferationQuiescent cancer cellsCycle stateCancer stem cellsSame primary tumorNeoadjuvant therapyProliferative cancer cellsAdjuvant therapyClinical outcomesColorectal cancerPrimary tumorImmune cellsUntreated tumorsDiverse tumor typesUnique tumorProliferation indexProliferative index
2018
Quantitative CT analysis for the preoperative prediction of pathologic grade in pancreatic neuroendocrine tumors
Chakraborty J, Pulvirenti A, Yamashita R, Midya A, Gönen M, Klimstra D, Reidy D, Allen P, G. R, Simpson A. Quantitative CT analysis for the preoperative prediction of pathologic grade in pancreatic neuroendocrine tumors. 2018, 10575: 105751n. DOI: 10.1117/12.2293577.Peer-Reviewed Original ResearchArea under the receiver operating characteristic curvePancreatic neuroendocrine tumorsNeuroendocrine tumorsPrediction of pathological gradeFifty-five patientsQuantitative analysis of CT imagesQuantitative CT analysisReceiver operating characteristic curveAnalysis of CT imagesCell proliferative ratePanNET gradeG3 tumorsG1/G2 tumorsTumor gradeKi67 indexSomatostatin analogsSurgical specimensProliferative indexPancreatic tumorsOptimal therapyPathological examinationPreoperative predictionCytotoxic drugsPathological gradeRetrospective analysis
2016
Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential
Gill RM, Buelow B, Mather C, Joseph NM, Alves V, Brunt EM, Liu TC, Makhlouf H, Marginean C, Nalbantoglu I, Sempoux C, Snover DC, Thung SN, Yeh MM, Ferrell LD. Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential. Human Pathology 2016, 54: 143-151. PMID: 27090685, PMCID: PMC5242228, DOI: 10.1016/j.humpath.2016.03.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCell ProliferationClass I Phosphatidylinositol 3-KinasesDiagnosis, DifferentialDNA Mutational AnalysisFemaleGTP-Binding Protein alpha Subunits, Gq-G11Hemangioma, CavernousHemangiosarcomaHumansImmunohistochemistryKi-67 AntigenLiver NeoplasmsMaleMiddle AgedMutationNeoplasm GradingPhosphatidylinositol 3-KinasesPredictive Value of TestsProto-Oncogene Proteins c-mycTerminology as TopicTumor Suppressor Protein p53Vascular NeoplasmsYoung AdultConceptsHepatic small vessel neoplasmMalignant potentialCavernous hemangiomaVascular neoplasmImmunohistochemical stainsProliferative indexKi-67 proliferative indexTumour cell proliferative indexDisseminated intravascular coagulationKasabach-Merritt syndromePossible malignant potentialLow-grade tumorsUncertain malignant potentialRare vascular neoplasmCapture-based next-generation sequencingHistologic differential diagnosisCell proliferative indexC-myc stainingStrong p53Intravascular coagulationComplete resectionHepatic angiosarcomaDifferential diagnosisInfiltrative bordersAngiosarcomaWell-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Tang L, Untch B, Reidy D, O'Reilly E, Dhall D, Jih L, Basturk O, Allen P, Klimstra D. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clinical Cancer Research 2016, 22: 1011-1017. PMID: 26482044, PMCID: PMC4988130, DOI: 10.1158/1078-0432.ccr-15-0548.Peer-Reviewed Original ResearchConceptsDisease-specific survivalWD-NETsPD-NECsHigh-grade componentNeuroendocrine tumorsGroup of aggressive neoplasmsMedian disease-specific survivalPoor-differentiated neuroendocrine carcinomasHigh-grade neuroendocrine neoplasmsHigh-grade NECsHigh-grade neoplasmsLow-intermediate gradeGene mutation analysisMetastatic sitesNeuroendocrine carcinomaPrimary tumorNeuroendocrine neoplasmsProliferative indexAggressive neoplasmClinical presentationDismal outcomeRadiographic featuresHigh-gradeBile ductPrimary site
2013
Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate
McCall C, Shi C, Cornish T, Klimstra D, Tang L, Basturk O, Mun L, Ellison T, Wolfgang C, Choti M, Schulick R, Edil B, Hruban R. Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate. The American Journal Of Surgical Pathology 2013, 37: 1671-1677. PMID: 24121170, PMCID: PMC3891823, DOI: 10.1097/pas.0000000000000089.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiopsyCell DifferentiationCell ProliferationFemaleHumansImmunohistochemistryKaplan-Meier EstimateKi-67 AntigenMaleMiddle AgedMitotic IndexNeoplasm GradingNeoplasm InvasivenessNeuroendocrine TumorsPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsYoung AdultConceptsGrade 1 tumorsKi67 proliferative indexPancreatic neuroendocrine tumorsOverall survivalProliferative indexMitotic rateMitotic gradeWorld Health OrganizationNeuroendocrine tumorsHistological featuresWell-differentiated pancreatic neuroendocrine tumorsWorld Health Organization grade 2Grade 2Metastasis to lymph nodesGrade 1Grading of PanNETAggressive histological featuresSmall vessel invasionInfiltrative growth patternShorter overall survivalDigital image analysis softwareKi67 gradeKi67/MIB-1Median survivalPerineural invasion
2012
Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System
Tang L, Gonen M, Hedvat C, Modlin I, Klimstra D. Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System. The American Journal Of Surgical Pathology 2012, 36: 1761-1770. PMID: 23026928, DOI: 10.1097/pas.0b013e318263207c.Peer-Reviewed Original ResearchMeSH KeywordsCell DifferentiationCell ProliferationClinical CompetenceClinical Laboratory TechniquesHumansImage Processing, Computer-AssistedImmunohistochemistryIntestinal NeoplasmsIntestine, SmallKi-67 AntigenNeoplasm GradingNeuroendocrine TumorsObserver VariationPancreatic NeoplasmsPredictive Value of TestsPrognosisRectal NeoplasmsReproducibility of ResultsConceptsNeuroendocrine tumorsKi67 assessmentWorld Health OrganizationGold standardProliferative rateTumor cell proliferative rateDetermination of therapeutic strategyGrade neuroendocrine tumorsKi67 labeling indexIntraclass correlationKi67 proliferative indexDetermination of prognosisDigital image analysisIntraobserver consistencyCell proliferative rateKi67 percentageGroup tumorsKi67 scoreTumor gradeKi67 indexPrognostic stratificationProliferative indexClinicopathological characteristicsKi67 labelingLabeling index
2008
Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1
Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Human Molecular Genetics 2008, 17: 1505-1516. PMID: 18263604, PMCID: PMC2902289, DOI: 10.1093/hmg/ddn039.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisButadienesCell ProliferationCystsDisease Models, AnimalEnzyme ActivationKidneyMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMice, Mutant StrainsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NitrilesPolycystic Kidney, Autosomal DominantProtein Kinase InhibitorsTRPP Cation ChannelsConceptsCyst formationERK1/2 activationPostnatal day 21Renal cystic diseaseWeeks of birthCyst cell proliferationPolycystic kidney diseaseKinase pathwayKidney tubule cellsKidney-specific inactivationRenal failureMEK1/2 inhibitor U0126Kidney diseaseCystic diseaseMAPK/ERKMAPK/ERK activationPresence of ciliaProliferative indexCyst growthCyst expansionDay 21Tubule cellsBrdU uptakeCystic kidneysBromodeoxyuridine incorporation
1999
Tumor Necrosis Factor-α Stimulates Proliferation of Rat Ovarian Theca-Interstitial Cells1
Spaczynski R, Arici A, Duleba A. Tumor Necrosis Factor-α Stimulates Proliferation of Rat Ovarian Theca-Interstitial Cells1. Biology Of Reproduction 1999, 61: 993-998. PMID: 10491635, DOI: 10.1095/biolreprod61.4.993.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeTNF-alphaTheca-interstitial cellsOvarian theca-interstitial cellsRat Ovarian Theca-Interstitial CellsInsulin-like growth factor ISerum TNF-alphaGrowth factor II cell proliferationDose-dependent fashionCytometry DNA analysisEffect of insulinOvary syndromeOvarian functionRat TTumor necrosisPathophysiologic roleTotal cell countProliferative indexCell countPotent modulatorFactor IIncorporation assayIGFInsulin
1993
Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve
Seifer D, Charland C, Berlinsky D, Penzias A, Haning R, Naftolin F, Barker B. Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve. American Journal Of Obstetrics And Gynecology 1993, 169: 1531-1535. PMID: 8267057, DOI: 10.1016/0002-9378(93)90430-q.Peer-Reviewed Original ResearchConceptsSerum follicle-stimulating hormone levelsFollicle-stimulating hormone levelsFollicle-stimulating hormoneLuteinized granulosa cellsIU/L.Ovarian reserveHormone levelsProliferative indexGranulosa cellsHormone groupChronologic agePreovulatory folliclesDay 3 follicle-stimulating hormone levelsHigh follicle-stimulating hormoneLower follicle-stimulating hormoneSerum follicle-stimulating hormoneFlow cytometryHuman luteinized granulosa cellsGreater proliferative indexSame chronologic ageWoman's ovarian reserveOvulation induction protocolsProspective cohort studyAdvanced reproductive ageIU/LGonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content
Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RV, Flynn SD. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content. The Journal Of Clinical Endocrinology & Metabolism 1993, 76: 711-714. PMID: 8445031, DOI: 10.1210/jcem.76.3.8445031.Peer-Reviewed Original ResearchConceptsHuman menopausal gonadotropinCell cycle kineticsProliferative indexGranulosa cellsFollicular fluidControl groupCycle kineticsGnRH analogue leuprolideOvulation induction regimensFollicular fluid contentMüllerian-inhibiting substanceHuman granulosa cellsLuteinized granulosa cellsCI (3.2-3.6) PInduction regimensMenopausal gonadotropinOocyte retrievalAndrogen contentGnRHSpecific growth factorsFlow cytometryGrowth factorFolliclesFluid contentOne-way analysis
1992
Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen
Seifer DB, Honig J, Penzias AS, Lavy G, Nadkarni PM, Jones EE, DeCherney AH, Flynn SD. Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 636-640. PMID: 1639962, DOI: 10.1210/jcem.75.2.1639962.Peer-Reviewed Original ResearchConceptsHuman menopausal gonadotropinOvulation induction regimenGreater proliferative indexInduction regimenLeuprolide acetateProliferative indexGranulosa cellsGroup IGroup IIGroup IIIAmpules of hMGFunction of ageFlow cytometryDay of hCGProspective cohort studyGroup of patientsHuman granulosa cellsChronological ageMenopausal gonadotropinCohort studyOvulation inductionSerum FSHSignificant independent influenceOutcome measuresWomen's age
1983
Duodenal epithelial thymidine uptake in patients with duodenal ulcer or endoscopic duodenitis
Gorelick F, Deluca V, Sheahan D, Marignani P, Goldblatt R, Winnan J, Livstone E. Duodenal epithelial thymidine uptake in patients with duodenal ulcer or endoscopic duodenitis. Digestive Diseases And Sciences 1983, 28: 392-396. PMID: 6839902, DOI: 10.1007/bf02430526.Peer-Reviewed Original ResearchConceptsEndoscopic duodenitisDuodenal ulcerControl subjectsDuodenal mucosaProliferative indexControl groupChronic active duodenitisDuodenal ulcer diseaseEpithelial cell renewalActive duodenitisChronic duodenitisDuodenal ulcerationMucosal biopsiesUlcer diseaseInflammatory processDuodenitisGastrointestinal tractHistologic appearanceEpithelial proliferationPatientsUlcersCrypt sizeThymidine uptakeMucosaCell renewal
1981
Is gastroduodenitis part of the spectrum of peptic ulcer disease?
DeLuca VA, Winnan GG, Sheahan DG, Sanders FJ, Greenlaw R, Marignani P, Gorelick FS, Bhalotra R, Goldblatt RS. Is gastroduodenitis part of the spectrum of peptic ulcer disease? Journal Of Clinical Gastroenterology 1981, 3: 17-22. PMID: 7320465.Peer-Reviewed Original ResearchConceptsPeptic ulcer diseaseUlcer diseasePeptic ulcerDifferent pathogenetic mechanismsSimilar clinical picturePreliminary dataAcute gastroduodenitisDuodenitis patientsGastrointestinal symptomsDuodenal ulcerUlcer craterAtypical manifestationsClinical pictureProspective studyGastric ulcerControl subjectsPathogenetic mechanismsHistologic studyTreatment responseBland dietGastroduodenitisPatientsProliferative indexThymidine uptakeUlcers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply